DDU of Nebulisers
The delivered dose testing of a nebulisers is carried out to determine the total amount of drug a patient might be expected to receive during a treatment period, rather than through one inhalation. Given the mode of operation of nebulisers, well-defined tidal breathing profiles for specific patient types are specified for testing. The two tests specified in the Pharmacopoeias to characterise delivered dose, Active Substance Delivery Rate and Total Active Substance Delivered, are based on tidal flow conditions generated by a breathing simulator, as opposed to fixed flow rates.
Breathing Simulator BRS 100i
View ProductFilter Holder and Adapter
View BrochureMouthpiece Adapter
View ProductAngle Adapter (for BRS 100i only)
View BrochureBRS 200i Breathing Simulator
View ProductAPSD of Nebulisers
View SystemBreathing Simulator BRS 100i
View ProductFilter Holder and Adapter
View BrochureMouthpiece Adapter
View ProductAngle Adapter (for BRS 100i only)
View BrochureBRS 200i Breathing Simulator
View ProductAPSD of Nebulisers
View SystemRelated Applications
We also offer a range of equipment for additional MDI testing application support:
Related Applications
Two factors have been identified as being critical to improving the clinical relevance of DDU testing and APSD measurement: realistic breathing profiles and realistic throat and nasal models.
View MoreRelated Applications
One of the main factors influencing the amount of inhaled drug available to the patient is the interface between the facemask and the patient. Investigating and defining the effect of a facemask to the product’s DDU and APSD is important for the product development.
View MoreRelated Services

Training
We offer a range of training courses, presentations and seminars covering a wide range of topics.
Find Out More
Servicing
A comprehensive range of both in-house and on-site product servicing options are available
Find Out More
Support
Our team of experienced technicians and engineers are on hand to help and advise
Find Out MoreRelated News & Resources

Copley introduces the new Flow Rate Sensor, a dedicated device for inhaler testing systems.
27 June 2023; Nottingham, UK: The new Flow Rate Sensor FRS is the latest addition to Copley Scientific’s orally inhaled and nasal drug product…
Find Out More
The new DUSA Shaker™ DTS 100i from Copley: For faster, safer, more repeatable inhaler testing
8th February 2023; Nottingham, UK: The DUSA Shaker™ DTS 100i is a new semi-automation solution from Copley Scientific, the global leader in inhaler and…
Find Out More
Copley launches EnviroMate™, an efficient, benchtop environmental chamber for inhaler testing
14 September 2022; Nottingham, UK: EnviroMate™ is a benchtop environmental control chamber from Copley, the world’s leading manufacturer and supplier of inhaler testing equipment,…
Find Out More
Copley Scientific joins the Industries Forum of the Taskforce for Lung Health
23 June 2021; Nottingham, UK: Copley Scientific has joined the Industries Forum of the Taskforce for Lung Health. The Taskforce is a collaboration of over…
Find Out More
Copley announces a major upgrade of the world’s ‘go to’ inhaler testing portfolio
01 March 2021, Nottingham, UK: Copley Scientific, the global leaders in inhaler testing equipment, is marking the company’s 75th anniversary with a significant upgrade…
Find Out More
New e-Training service from Copley for pharmaceutical testing
14 January 2021; Nottingham, UK: Copley Scientific is now delivering e-Training, offering customers across the globe remote access to expert tuition on in vitro…
Find Out More
Copley launches a new webinar series on inhaler testing
20 April 2020; Nottingham, UK: Copley Scientific will shortly begin the company’s inaugural series of technical webinars, offering valuable, easy to understand overviews on…
Find Out More
Advancing the science of OINDPs: Copley Scientific joins IPAC-RS
28 February 2018; Nottingham, UK: Copley Scientific, a global leader in the design and manufacture of inhaler testing equipment, is pleased to announce that…
Find Out More
More precise nebuliser testing as Copley Scientific launches NGI Cooler
29 April 2009; Nottingham, UK: The new NGI Cooler from Copley Scientific is a practical, easy to use system that improves the accuracy and…
Find Out More
Q&A: OINDPnews 2022
Reducing Inhaler Testing Variability Through Test Environment Control In this Q&A with OINDPnews, our CEO Mark Copley answers questions about the importance of the…
Find Out More
DDD 2021 Respiratory eBook Profile
Semi-Automating Inhaler Testing – A Good Idea, but Where to Start? Cascade impaction is a vital technique in the development and manufacture of orally…
Find Out More
PMPS Q&A (Samedan): April 2021
Putting Inhalers to the Test Anna Sipitanou has worked for Copley Scientific for four years, expanding her drug discovery and pharma science background. She…
Find Out More
Microbioz India: February 2021
A short Q&A with our CEO, Mark Copley, on inhaled product testing
Find Out More
Inhalation Article: December 2019
Optimizing the role of automation in variability reduction strategies for delivered dose uniformity (DDU) and aerodynamic particle size distribution (APSD) testing of inhaled drug…
Find Out More
Inhalation Article: April 2019
The regulatory landscape for OINDPs – the biggest shake-up in a generation?
Find Out More
Drug Development & Delivery Article: April 2018
Optimizing the Application of In Vitro Test Methods for the Demonstration of Bioequivalence in Orally Inhaled Products
Find Out More
PMPS Article (Samedan): February 2018
Demonstrating Bioequivalence of Orally Inhaled Products Safe and cost-effective treatments for respiratory diseases are facing a growing demand. The demonstration of bioequivalence within locally…
Find Out More
White Paper: February 2018
Optimising the application of in vitro test methods for the demonstration of BE in OIPs
Find Out MoreHave a question? Our friendly and experienced team are here to help.